HSR 175

Drug Profile

HSR 175

Latest Information Update: 20 May 1998

Price : $50

At a glance

  • Originator Hokuriku Seiyaku
  • Class Antihypertensives; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Benign prostatic hyperplasia; Hypertension

Most Recent Events

  • 20 May 1998 Discontinued-Preclinical for Benign prostatic hyperplasia in Japan (Unknown route)
  • 20 May 1998 Discontinued-Preclinical for Hypertension in Japan (Unknown route)
  • 26 May 1997 No-Development-Reported for Benign prostatic hyperplasia in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top